Open an account

XBiotech

XBIT · NASDAQ

$2.02+$0.02 (+1.00%)TodayMarket closed ·
Prev close $2.00

About XBIT

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2015-04-15. The firm's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The firm is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. The company has various candidate products, including Natrunix. The company has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Employees
85
Headquarters
Austin, Texas
Listed
Apr 15, 2015
Sector
Health Care
Industry
Biotechnology
Website
xbiotech.com

XBIT key statistics

Market cap
68.29M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
59.85K
Volume
41.24K
Open price
$2.03
High today
$2.08
Low today
$1.99
52 Week high
$3.44
52 Week low
$1.91

XBiotech (XBIT) at a glance

XBiotech (XBIT) last traded at $2.02, with a market cap of 68.29M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.99 and $2.08. The current price is 1.5% above the day's low and 2.9% below its high.

Volume so far is 41.24K shares, below the average of 59.85K shares a day.

Over the past year XBiotech has ranged from $1.91 to $3.44, and now sits 7% of the way up that range.

XBiotech met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q1 FY20 it reported $0.00 per share against an estimate of $0.0612.

XBIT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 2422.5% on average.

  1. Q2 FY16: reported -$0.42 per share against an estimate of -$0.357
  2. Q3 FY16: reported -$0.38 per share against an estimate of -$0.4692
  3. Q4 FY16: reported -$0.51 per share against an estimate of -$0.4284
  4. Q1 FY17: reported -$0.32 per share against an estimate of -$0.4794
  5. Q2 FY19: reported -$0.16 per share against an estimate of -$0.153
  6. Q3 FY19: reported -$0.15 per share against an estimate of -$0.153
  7. Q4 FY19: reported $14.59 per share against an estimate of -$0.153
  8. Q1 FY20: reported $0.00 per share against an estimate of $0.0612

XBIT news

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

  • Press releasePRNewswire

    XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

  • Press releaseGlobe Newswire

    Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

  • Press releaseBusiness Wire

    XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT

Similar companies

Companies in the same industry as XBiotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.